Sanofi Bets Big On IO With Synthorx Buy
Expects Interleukin-2 To Be Foundation Of Future IO-IO Combos
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
